AbbVie Inc. (NYSE:ABBV) Shares Sold by Revisor Wealth Management LLC

Revisor Wealth Management LLC decreased its stake in shares of AbbVie Inc. (NYSE:ABBV - Free Report) by 43.6% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,324 shares of the company's stock after selling 1,797 shares during the quarter. Revisor Wealth Management LLC's holdings in AbbVie were worth $416,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of ABBV. Ball & Co Wealth Management Inc. purchased a new stake in shares of AbbVie during the 4th quarter worth $393,000. Warm Springs Advisors Inc. acquired a new stake in AbbVie in the fourth quarter valued at $2,060,000. North Star Asset Management Inc. lifted its holdings in AbbVie by 1.9% during the 4th quarter. North Star Asset Management Inc. now owns 160,564 shares of the company's stock worth $28,532,000 after buying an additional 3,004 shares during the last quarter. Retirement Planning Group LLC NY purchased a new stake in AbbVie during the 4th quarter worth about $719,000. Finally, GF Fund Management CO. LTD. acquired a new position in shares of AbbVie during the 4th quarter worth about $7,687,000. Institutional investors and hedge funds own 70.23% of the company's stock.

Insiders Place Their Bets

In other AbbVie news, EVP Timothy J. Richmond sold 29,917 shares of the stock in a transaction that occurred on Wednesday, February 26th. The shares were sold at an average price of $202.90, for a total transaction of $6,070,159.30. Following the transaction, the executive vice president now owns 44,284 shares of the company's stock, valued at $8,985,223.60. This trade represents a 40.32% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Jeffrey Ryan Stewart sold 58,832 shares of the business's stock in a transaction on Monday, March 31st. The shares were sold at an average price of $210.08, for a total transaction of $12,359,426.56. Following the sale, the executive vice president now directly owns 53,234 shares of the company's stock, valued at $11,183,398.72. This represents a 52.50% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 107,693 shares of company stock valued at $22,282,985. Company insiders own 0.08% of the company's stock.

AbbVie Price Performance

ABBV stock traded up $2.26 during trading on Tuesday, hitting $185.52. The stock had a trading volume of 5,720,849 shares, compared to its average volume of 6,252,208. The stock has a market cap of $327.70 billion, a price-to-earnings ratio of 77.30, a price-to-earnings-growth ratio of 1.62 and a beta of 0.56. The company has a debt-to-equity ratio of 17.94, a quick ratio of 0.55 and a current ratio of 0.66. The company's 50 day moving average price is $187.82 and its two-hundred day moving average price is $186.11. AbbVie Inc. has a 1-year low of $153.58 and a 1-year high of $218.66.

AbbVie (NYSE:ABBV - Get Free Report) last issued its quarterly earnings results on Friday, April 25th. The company reported $2.46 EPS for the quarter, topping analysts' consensus estimates of $2.40 by $0.06. The business had revenue of $13.34 billion during the quarter, compared to the consensus estimate of $12.91 billion. AbbVie had a net margin of 7.59% and a return on equity of 296.28%. The company's quarterly revenue was up 8.4% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.31 earnings per share. On average, sell-side analysts forecast that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have commented on ABBV shares. Wells Fargo & Company increased their price target on shares of AbbVie from $210.00 to $240.00 and gave the company an "overweight" rating in a research note on Wednesday, March 5th. UBS Group increased their price target on shares of AbbVie from $181.00 to $190.00 and gave the stock a "neutral" rating in a research note on Monday, February 3rd. Wall Street Zen downgraded AbbVie from a "strong-buy" rating to a "buy" rating in a research note on Thursday, May 22nd. Morgan Stanley increased their price target on shares of AbbVie from $241.00 to $250.00 and gave the stock an "overweight" rating in a report on Monday, April 28th. Finally, Truist Financial lifted their price target on AbbVie from $211.00 to $217.00 and gave the company a "buy" rating in a research note on Monday, February 3rd. Eight research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and three have given a strong buy rating to the company. According to MarketBeat.com, AbbVie presently has an average rating of "Moderate Buy" and a consensus price target of $210.95.

AbbVie Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.